Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan  by Liu, Hsin-Yi et al.
Journal of Microbiology, Immunology and Infection (2011) 44, 364e368ava i lab le at www.sc iencedi rect .com
journal homepage: www.e- jmi i . comORIGINAL ARTICLE
Antimicrobial susceptibilities of urinary extended-
spectrum beta-lactamase-producing Escherichia
coli and Klebsiella pneumoniae to fosfomycin and
nitrofurantoin in a teaching hospital in TaiwanHsin-Yi Liu a, Hsiu-Chen Lin b, Yi-Chun Lin a,c, Shao-hua Yu b,c, Wui-Hsiu Wu a,
Yuarn-Jang Lee a,c,*aDepartment of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan
bDepartment of Laboratory Medicine, Taipei Medical University Hospital, Taipei, Taiwan
cDepartment of Infection Control, Taipei Medical University Hospital, Taipei, Taiwan
Received 20 April 2010; received in revised form 20 July 2010; accepted 19 August 2010KEYWORDS
ESBL;
Escherichia coli;
Extended-spectrum
beta-lactamase;
Fosfomycin;
Klebsiella pneumoniae;
Nitrofurantoin* Corresponding author. Department
E-mail address: yuarn438@yahoo.c
1684-1182/$36 Copyright ª 2011, Taiw
doi:10.1016/j.jmii.2010.08.012Background: Urinary tract infections (UTIs) caused by extended-spectrum b-lactamase (ESBL)-
producing Escherichia coli and Klebsiella pneumoniae have become clinical problems because
of limited therapeutic options. The role of fosfomycin in the era of growing bacteria resistance
has been widely discussed recently. In this study, we aimed to know the local antimicrobial
susceptibilities, fosfomycin susceptibility in particular, of urinary ESBL-producing E coli and
K pneumoniae isolates in Taiwan.
Methods: We collected 200 urine isolates, including 134 ESBL-producing E coli (ESBL-EC ) and
66 ESBL-producing K pneumoniae (ESBL-KP) isolates from July 2008 to December 2009 in
a university-affiliated teaching hospital in Taiwan. We used disk diffusion method to determine
susceptibility to fosfomycin. Fosfomycin may have lower susceptibility when using disk diffu-
sion method compared with agar dilution method. Broth microdilution test was also used to
determine minimal inhibitory concentrations (MICs) and susceptibilities to other antimicrobial
agents.
Results: Imipenem was active against ESBL-EC and ESBL-KP. Fosfomycin had good susceptibility
to ESBL-EC (95.5%), including in hospital-acquired isolates, but lower antimicrobial activity
against ESBL-KP (57.6%). Trimethoprim-sulfamethoxazole had the highest resistance rate to
ESBL-EC and ESBL-KP. Comparing with non-hospital-acquired isolates, hospital-acquired
ESBL-KP was associated with significantly lower susceptibility of gentamicin (13.3% vs.of Internal Medicine, Taipei Medical University Hospital, No. 252, Wu-Hsin Street, Taipei 110, Taiwan.
om.tw (Y.-J. Lee).
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Urinary ESBL E coli and K pneumoniae 36566.7%), trimethoprim-sulfamethoxazole (8.9% vs. 38.1%), ciprofloxacin (26.7% vs. 61.9%), and
amikacin (46.1% vs. 81.0%) (p< 0.05). The resistance of some strains to ciprofloxacin was
significantly associated with lower susceptibilities of gentamicin (32.6% in ESBL-EC ), nitrofur-
antoin (2.4% in ESBL-KP) and trimethoprim-sulfamethoxazole (9.8% in ESBL-KP) (p< 0.05) but
not accompanied with decreasing susceptibility of fosfomycin.
Conclusion: Fosfomycin had the excellent activity against ESBL-EC but not ESBL-KP in this
study. Based on the study findings, we suggest that fosfomycin can be a therapeutic option
for UTIs with ESBL-EC. Nitrofuranoin was actively against ESBL-EC. Nitrofurantoin may be an
alternative option for uncomplicated UTIs with ESBL-EC in Taiwan.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Escherichia coli and Klebsiella pneumoniae are the most
common pathogens causing urinary tract infection (UTI).
Extended-spectrum b-lactamase (ESBL) produced by E coli
and K pneumoniae reduces the number of therapeutic
options for the infection caused by these pathogens.1,2
ESBL-producing E coli (ESBL-EC ) and ESBL-producing
Kpneumoniae (ESBL-KP) are resistant to penicillins, ceph-
alosporins, and monobactams. The ESBL producers can also
develop coresistance to other classes of antimicrobial
agents, such as fluoroquinolones, co-trimoxazole, and
aminoglycosides,3 which are frequently used for UTI.
Fosfomycin, which has bactericidal properties against
various gram-positive and gram-negative bacteria, can inhibit
UDP-N-acetylflucoamine enolpyruvyl transferase (MurA), an
enzyme catalyzing the early step in bacterial cell wall
synthesis.4,5 This antimicrobial agent has been used to treat
UTI for nearly 40 years. Fosfomycin is increasingly important
to treat UTI because the resistance rate of uropathogens to
common antimicrobial agents is increasing. But, as we know,
the antimicrobial susceptibility of enterobacteriaceae to
fosfomycin has not been assessed yet in Taiwan.
In this study, we aimed to evaluate the antimicrobial
activities of fosfomycin and other common antimicrobials
against the ESBL-EC and ESBL-KP isolates from urine.
Methods
Bacterial isolates
We chose urinary isolates of ESBL-EC and ESBL-KP, which
were collected and identified between July 2008 and
December 2009 in the microbiological laboratory of the
Taipei Medical University Hospital, one of Taipei Medical
University-affiliated teaching hospitals. We excluded
duplicate isolates, which were defined as isolation of the
same bacterial species from the same patient with the
same antibiogram. We identified the species of E coli and
K pneumoniae with the Phoenix automated system
(Phoenix; Becton Dickinson, Sparks, MD, USA). Identifica-
tion of ESBL production was done using phenotypic testing
based on the demonstration of synergy between clavulanic
acid and broad-spectrum cephalosporins according to
Clinical and Laboratory Standards Institute (CLSI) guide-
line.6 Hospital-acquired urinary isolates were collected 2
days after admission,7,8 or collected from patients whowere discharged within 30 days (either our facility or other
facilities if recorded in chart).
Antimicrobial susceptibility testings
The broth microdilution method (Phoenix; Becton Dick-
inson, Sparks, MD, USA) was used to test the antimicrobial
susceptibilities for the commonly used antibiotics,
including ciprofloxacin, nitrofurantoin, gentamicin, amika-
cin, trimethoprin-sulfamethaxole, and imipenem. The
breakpoints of these antimicrobial agents were using CLSI
criteria.6 With regard to the antimicrobial activity of fos-
fomycin, we used the CLSI-directed disk diffusion test for E
coli and K pneumoniae, although the standard breakpoints
of disk zone diameter were only issued for E coli but not for
K pneumoniae.
Statistical analyses
We compared the differences in susceptibility or resistance
between the groups with c2 test. The difference between
groups were considered significantly different if p-values
were smaller than 0.05. We analyzed the data with Statis-
tical Package for the Social Sciences software for Windows
Version 16.0 (SPSS, Inc., Chicago, IL, USA).
Result
We included 134 isolates of ESBL-EC and 66 isolates of ESBL-
KP in the study. We tested seven antimicrobial agents
(fosfomycin, nitrofurantoin, ciprofloxacin, gentamicin,
trimethoprim-sulfamethoxazole, amikacin, and imipenem)
for those 200 isolates. Table 1 is the comparison of anti-
microbial susceptibilities in ESBL-EC and ESBL-KP. We found
that imipenem was the most active antimicrobial agent
against all the ESBL-EC and ESBL-KP isolates, with suscep-
tibility rates of 99.3% and 90.9%, respectively. Only 57.6% of
ESBL-KP isolates were susceptible to amikacin. Fosfomycin,
showed significantly higher antimicrobial activity against
ESBL-EC than ESBL-KP, with susceptibility of 95.5% and
57.6%, respectively (p< 0.001). The susceptibility rate of
nitrofurantoin against ESBL-EC isolates was near 80% but
was significantly decreased in ESBL-KP isolates (p< 0.001).
Among the 200 isolates of urinary ESBL-EC and ESBL-KP,
64 (47.8%) ESBL-EC isolates and 45 (68.2%) ESBL-KP isolates
were compatible with definition of hospital-acquired
isolates. Table 2 lists the antimicrobial susceptibilities of
Table 1 Comparison of antimicrobial susceptibilities between ESBL-producing E coli and ESBL-producing K pneumoniae
Antibiotic ESBL-EC (nZ 134) ESBL-KP (nZ 66) p
S (%) MIC90 (mg/L) S(%) MIC90 (mg/L)
Fosfomycin 95.5 57.6 <0.001
Nitrofurantoin 79.1 >128 13.6 >128 <0.001
Ciprofloxacin 29.1 >4 37.9 >4 0.276
Gentamicin 44.8 >16 30.3 >16 0.049
Trimethoprim-sulfamethoxazole 22.4 >4 18.2 >4 0.492
Amikacin 97.0 8 57.6 >64 <0.001
Imipenem 99.3 1 90.9 4 0.003
ESBL-ECZ extended-spectrum b-lactamase producing Escherichia coli; ESBL-KPZ extended-spectrum b-lactamase producing Klebsiella
pneumoniae; MICZminimal inhibition concentration; SZ susceptibility.
Significantly different if p< 0.05.
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and ESBL-KP isolates. None of the antimicrobials tested had
significant difference in activity against the hospital-
acquired or non-hospital-acquired ESBL-EC isolates. Imipe-
nem (susceptibility rate 91.1%) was still actively against the
hospital-acquired ESBL-KP, followed by fosfomycin
(susceptibility rate 55.6%), and amikacin (susceptibility
rate 46.7%). Amikacin (susceptible rate 81%) was still
actively against non-hospital-acquired ESBL-KP isolates.
Less than 30% hospital-acquired urinary ESBL-producing
isolates were susceptible to ciprofloxacin.
Table 3 characterizes the antimicrobial susceptibilities
of the ESBL-EC and ESBL-KP isolates with respect to cipro-
floxacin resistance. Imipenem, fosfomycin, and amikacin
had good activity against both ciprofloxacin- susceptible
and ciprofloxacin nonsusceptible ESBL-EC isolates. The
susceptible rate of gentamicin was significantly lower in
ciprofloxacin nonsusceptible ESBL-EC isolates comparing
with ciprofloxacin-susceptible isolates (32.6% vs. 74.4%
isolates, p< 0.001). Among ESBL-KP isolates, imipenem still
showed high activity in both groups. Fosfomycin has higher
activity against ciprofloxacin-sensitive group but without
statistical significance comparing with ciprofloxacin non-
susceptible group (pZ 0.181). Comparing with cipro-
floxacin-susceptible group, the susceptible rates of ESBL-KP
isolates for nitrofurantoin and trimethoprim-sulfamethox-
azole were significantly decreased in the ciprofloxacinTable 2 Antimicrobial susceptibilities of hospital-acquired a
producing K. pneumoniae isolates
Antibiotic ESBL-EC
HA (nZ 64) Non-HA (nZ
Fosfomycin 96.9 94.3
Nitrofurantoin 76.6 81.4
Ciprofloxacin 25.0 32.9
Gentamicin 42.2 47.1
Trimethoprim-sulfamethoxazole 20.3 24.3
Amikacin 95.3 98.6
Imipenem 100 98.6
ESBL-ECZ extended-spectrum b-lactamase producing Escherichia coli
pneumoniae; HAZ hospital acquired.
Significantly different if p< 0.05.nonsusceptible isolates (32.0% vs. 2.4%, pZ 0.001; 32% vs.
9.8%, pZ 0.023; respectively).
Discussion
E coli and K pneumoniae play important roles in UTI, which
is one of the most frequently encountered infectious
diseases. Cephalosporins and trimethoprim-sulfamethox-
azole are widely used in treating UTI. Because of the rising
resistance of E coli to trimethoprim-sulfamethoxazole,
fluoroquinolones has been used more frequently. But the
production of ESBLs by E coli and K pneumoniae is associ-
ated with the reducing susceptibility to fluoroquinolones
and other antimicrobial agents.9e13 Ciprofloxacin has
commonly been used as oral therapeutic option for ESBL-
producing isolates. The resistance rates of ESBL-EC and
ESBL-KP to ciprofloxacin in this study (Table 1) were higher
than those reported from other countries. In the last two
decades, ESBL-producing enterobacteriaceae have
emerged in both the community and hospital settings in
most countries, including Taiwan.9,13e18 Carbapenems are
the drugs of choice for treating severe infections caused by
the ESBL-producing isolates. In our study, imipenem was
most actively against ESBL-EC and ESBL-KP isolates.
Aminoglycosides are therapeutic alternatives to ESBL-
producing enterobacteriaceae. Gentamicin was inactivend non-hospital-acquired ESBL-producing E. coli and ESBL-
p ESBL-KP p
70) HA (nZ 45) Non-HA (nZ 21)
0.469 55.6 61.9 0.627
0.489 11.1 19.0 0.382
0.317 26.7 61.9 0.006
0.564 13.3 66.7 <0.001
0.582 8.9 38.1 0.004
0.268 46.7 81.0 0.009
0.337 91.1 90.5 0.933
; ESBL-KPZ extended-spectrum b-lactamase producing Klebsiella
Table 3 Antimicrobial susceptibilities of ESBL-producing E coli and ESBL-producing K pneumoniae isolates with respect to
ciprofloxacin resistance
Antibiotic ESBL-EC p ESBL-KP p
CIP-S (nZ 39) CIP-NS (nZ 95) CIP-S (nZ 25) CIP-NS (nZ 41)
Fosfomycin 92.3 96.8 0.249 68.0 51.2 0.181
Nitrofurantoin 84.6 76.8 0.315 32.0 2.4 0.001
Gentamicin 74.4 32.6 <0.001 44.0 22.0 0.059
Trimethoprim-sulfamethoxazole 33.3 17.9 0.051 32.0 9.8 0.023
Amikacin 97.4 96.8 0.854 72.0 48.8 0.064
Imipenem 97.4 100 0.117 96.0 87.8 0.261
CIP-SZ ciprofloxacin-susceptible (MIC 1 mg/L); CIP-NSZ ciprofloxacin-resistant or intermediate (MIC 2 mg/L); ESBL-ECZ ex-
tended-spectrum b-lactamase producing Escherichia coli; ESBL-KPZ extended-spectrum b-lactamase producing Klebsiella pneumoniae.
Significantly different if p< 0.05.
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1), and amikacin exhibited similar activity to imipenem
against ESBL-EC. The activities of amikacin against ESBL-KP
are various in previous studies.12,13,19 According to SMART
2005e2007, Hawser et al.13 showed that 75.4% ESBL-KP
related to intraabdominal infection is susceptible toamikacin.
A study in New Zealand has reported zero resistance rate of
ESBL-KP to amikacin.19 The amikacin susceptibility rate in this
study is lower thanthat inpreviouspublisheddata inTaiwan.12
In this study, another potential drug, fosfomycin was
actively against ESBL-EC. Fosfomycin has been reported to
have good potential in treating UTI caused by multidrug-
resistant E coli.14,20,21 Fosfomycin is well tolerated in
humans and causes little nephrotoxicity. Fosfomycin-tro-
methamine, an oral form of fosfomycin, is also indicated
for uncomplicated UTI. In a systematic review, fosfomycin
is found actively against Enterobacteriaceae producing
ESBL, particularly E coli.22 Our study showed the similar
finding, and the activity of fosfomycin against ESBL-EC
isolates remained reliable even in ciprofloxacin-non-
susceptible isolates. Ko et al.14 has shown that fosfomycin
does not have cross-resistance with other antimicrobial
agents. This finding may be because of the unique anti-
bacterial mechanism of fosfomycin. The CLSI criteria of
fosfomycin have been issued for urinary E coli isolates.
Other national organizations, such as British Society for
Antimicrobial Chemotherapy and Antimicrobial Committee
of the French Microbiology Society, recommend fosfomycin
for other enterobacteriaceae, but with more conservative
criteria.23 But, the role of fosfomycin against K pneumoniae
has been widely discussed. In the review by Falagas et al.,22
the susceptibilities of ESBL-KP isolates to fosfomycin were
76.7% to 100%. But, in this study, ESBL-KP exhibited high
resistance rate to fosfomycin (42.4%) according to CLSI
criteria (Table 1). Hence, fosfomycin is a promising thera-
peutic option for treating inpatient and outpatient UTI
caused by ESBL-EC rather than ESBL-KP.
Nitrofurantoin is an old drug used for uncomplicated
UTI, but its use is limited because of its nephrotoxicity.
Recently, the potential role of nitrofurantoin for uncom-
plicated UTI in the growing resistance era has been
mentioned.24 In this study, the susceptibility rate of ESBL-
EC isolates for nitrofurantoin was near 80%, which was not
significantly changed in the presence of ciprofloxacin
resistance (Table 3). K pneumoniae isolates producing ESBLhas been reported to be associated with increased resis-
tance to nitrofurantoin.25 As shown in Table 3, our study
finding showed that the resistance rate was also increased
significantly in ciprofloxacin nonsusceptible ESBL-KP. Based
on those findings, we suggest that nitrofurantoin may be
another alternative option for treating uncomplicated UTI
caused by ESBL-EC infection.
Trimethoprim-sulfamethoxazole is one of few oral
therapeutic options for ESBL-producing isolates. But in this
study, it was the least active antimicrobial agent against
ESBL-EC and ESBL-KP isolates (Table 1). Ko et al.14 showed
that the resistance rates for trimethoprim-sulfamethox-
azole among E coli are rising accompanied with cipro-
floxacin resistance and ESBL production.
In hospital-acquired UTI caused by ESBL-producing E coli
and K pneumoniae, it is easy to use an inappropriate anti-
biotic as empiric therapy. The initial inappropriate therapy
for hospital-acquired infection is associated with higher
mortality.26 According to our data, imipenem, fosfomycin,
and amikacin were reliable for hospital-acquired ESBL-EC
(Table 2). None of ESBL-EC was resistant to imipenem, and
only two of three isolates were resistant to fosfomycin and
amikacin, respectively. With regard to hospital-acquired
ESBL-KP isolates, the activity was significantly lower in
amikacin, ciprofloxacin, gentamicin, and trimethoprim-
sulfamethoxazole (p< 0.05). Fosfomycin showed similarly
activity in the two groups. Amikacin was frequently used
for hospital-acquired UTI as combination therapy for broad-
spectrum covering. Patients with hospital-acquired infec-
tion have higher risk for nephrotoxicity, which is probably
related to amikacin because of comorbidity and unstable
hemodynamic status. Fosfomycin had similar activity as
amikacin against hospital-acquired ESBL isolates (Table 2).
We suggest that fosfomycin has the potential to replace
amikacin in treating hospital-acquired UTI when consid-
ering ESBL-producing isolates and less nephrotoxicity.
This study has two limitations. First, only disk diffusion
method was used to determine the fosfomycin suscepti-
bility. We did not keep all isolates for further MIC. de Cueto
et al.15 showed discrepancy between different methods
testing the susceptibility of ESBL-KP to fosfomycin, whereas
no significant difference has been found for E coli. Disk
diffusion method reported greater resistance to fosfomycin
for K pneumoniae than agar dilution method. Second,
the non-hospital-acquired group may include health
368 H.-Y. Liu et al.care-associated isolates from other health care institutions
or other hospital if not recorded in chart. It may decrease
the susceptible rates of antimicrobials in the non-hospital-
acquired group.
In conclusion, fosfomycin showed significantly higher
activity against ESBL-EC than ESBL-KP in this study. The
susceptibility to fosfomycin was also kept for hospital-
acquired ESBL-EC isolates. Fosfomycin may be a potential
therapeutic option for hospital- and community-acquired
UTI caused by ESBL-EC. Nitrofurantoin was actively against
ESBL-EC only. Nitrofurantoin may be another alternative
option for treating uncomplicated UTI caused by ESBL-EC in
Taiwan.
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